Phase II trial of cisplatin and etoposide in patients with metastatic melanoma

Abstract

Fourteen patients with metastatic melanoma were treated with cisplatin and etoposide by bolus intravenous infusion daily for 5 consecutive days each month. All patients were evaluable for toxicity and twelve for response. Eight patients were treated with cisplatin 20 mg/m 2 and etoposide 100 mg/m 2 daily. Because of excessive myelosuppression, the daily dose of etoposide was reduced to 75 mg/m 2 in the remaining six patients. There were no major responses among 12 evaluable patients (major response rate _< 24% with 95% confidence). The median time to progression was one month. One patient with a liver metastasis had a minor response lasting 6 + months. The combination of cisplatin and etoposide in these doses and schedule lacked sufficient clinical efficacy in the treatment of metastatic melanoma.

Pan‐cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours

“…According to the analysis results, etoposide is the prominent drug compound with which a significant number of genes were connected (Figure 8F). In a previous clinical trial, the combination of etoposide and cisplatin lacked sufficient clinical efficacy in the treatment of metastatic melanoma 31 . Our findings would indicate that pairing etoposide with the BRD9/7 inhibitor TP‐472 would likely improve clinical outcomes in patients with melanoma.…”

“…In a previous clinical trial, the combination of etoposide and cisplatin lacked sufficient clinical efficacy in the treatment of metastatic melanoma. 31 Our findings would indicate that pairing etoposide with the BRD9/7 inhibitor TP-472 would likely improve clinical outcomes in patients with melanoma.…”

Two Worlds Collide: Unraveling the Role of the Immune System in BRAF–MEK Inhibitor Responses

“…The authors did not determine whether etoposide restored T-cell infiltration to the resistant tumors-a potential issue given that drugs such as etoposide can be myelosuppressive. Although the results with etoposide were intriguing, it is worth noting that previous clinical experience of etoposide in melanoma has not been positive (11). It therefore remains to be determined whether etoposide will prove beneficial as a salvage therapy in patients with melanoma who have failed BRAF-MEK inhibitor therapy.…”